CBR3 and cardiovascular disorder: We found no statistically significant difference in age, history of cardiovascular diseases, risk factors for cardiovascular disease, cumulative DOX dose, or concurrent use of beta blockers or ACE inhibitors between CBR3 genotype groups (Table 1).